Skip to main content

Table 4 Radioimmunotherapy for primary/recurrent SCCHN (no prior RT)

From: Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience

tumor stages  
T1 8 pts  
T2 8 pts  
T3 3 pts  
T4 30 pts  
N0 15 pts  
N1 4 pts  
N2 31 pts  
N3 0 pts  
primary RT   
median dose (Gy) 66 [16 - 70,6]
IMRT 28 pts  
3D 9 pts  
conventional RT 9 pts  
RIT   
first treatment 38/51 pts  
RIT for disease relapse 13/51 pts  
> 1 cycle cetuximab 48/51 pts  
response (48 pts) at first follow-up
CR 10 pts
PR 19 pts
SD 2 pts
PD 5 pts
dna 5 pts
f/u unavailable 7 pts